CN103655538B - Hippolachnin A在治疗急性肾衰药物中的应用 - Google Patents

Hippolachnin A在治疗急性肾衰药物中的应用 Download PDF

Info

Publication number
CN103655538B
CN103655538B CN201310652101.2A CN201310652101A CN103655538B CN 103655538 B CN103655538 B CN 103655538B CN 201310652101 A CN201310652101 A CN 201310652101A CN 103655538 B CN103655538 B CN 103655538B
Authority
CN
China
Prior art keywords
renal failure
hippolachnin
acute renal
application
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310652101.2A
Other languages
English (en)
Other versions
CN103655538A (zh
Inventor
孙德宏
黄术胜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Haiwang Zhongxin Pharmaceutical Co.,Ltd.
Original Assignee
刘艳娇
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 刘艳娇 filed Critical 刘艳娇
Priority to CN201310652101.2A priority Critical patent/CN103655538B/zh
Publication of CN103655538A publication Critical patent/CN103655538A/zh
Application granted granted Critical
Publication of CN103655538B publication Critical patent/CN103655538B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

本发明涉及Hippolachnin A的新医药用途，即Hippolachnin A在制备治疗急性肾衰药物中的应用，在制备抗急性肾衰药物中的用途属于首次公开，由于骨架类型属于全新的骨架类型，而且其对于急性肾衰抑制活性强，具备突出的实质性特点，同时用于抗急性肾衰显然具有显著的进步。

Description

Hippolachnin A在治疗急性肾衰药物中的应用
技术领域
本发明涉及化合物Hippolachnin A的新用途，尤其涉及Hippolachnin A在制备治疗急性肾衰药物中的应用。
背景技术
急性肾功能衰竭(Acute Renal Failure，ARF)是由多种原因引起的临床综合征，其特点为短期内(数小时至数天)肾功能急剧下降，临床表现为急性少尿(尿量<400mLPd)或无尿(尿量<100mLPd)，体内氮质代谢产物排出产生障碍，迅速出现氮质血症，水及电解质、酸碱平衡紊乱，并引起全身各系统相应功能失调。引起急性肾衰的主要因素是肾血流量的急剧减少，以及由于肾组织缺血引起的氧化应激和细胞损伤，最终导致肾脏组织结构的破坏和功能的恶化。目前仅能通过纠正水电解质平衡，纠正酸中毒等对症治疗措施改善症状，后期还需要通过血液透析维持机体机能。在改善肾脏血流灌注障碍和减轻肾组织损伤方面有明显疗效的临床药物少见。
本发明涉及的化合物Hippolachnin A是一个2013年发表(Shu-Juan Piao，et al.,Hippolachnin A,a New Antifungal Polyketide from the South China Sea SpongeHippospongia lachne.Organic Letters，2013,15(14):3526–3529.)的新化合物，该化合物拥有全新的骨架类型，发现其能抗菌(Shu-Juan Piao，et al.,Hippolachnin A,a New Antifungal Polyketide from the South China Sea Sponge Hippospongia lachne.Organic Letters，2013,15(14):3526–3529.)，本发明涉及的Hippolachnin A在制备治疗急性肾衰药物中的用途属于首次公开。
发明内容
本发明的目的在于根据现有Hippolachnin A研究中未发现其具有抗急性肾衰活性的报道的现状，提供了Hippolachnin A在制备抗急性肾衰药物中的应用。
通过我们的研究发现，Hippolachnin A能够改善急性肾衰时的无尿或少尿症状，保护肾脏的功能。
所述化合物Hippolachnin A,结构如式(Ⅰ)所示：
本发明涉及的Hippolachnin A在制备抗急性肾衰药物中的用途属于首次公开，由于骨架类型属于全新的骨架类型，而且其对于急性肾衰抑制活性强，具备突出的实质性特点，同时用于抗急性肾衰显然具有显著的进步。
具体实施方式
以下通过实施例对本发明作进一步详细的说明，但本发明的保护范围不受具体实施例的任何限制，而是由权利要求加以限定。
本发明所涉及化合物Hippolachnin A的制备方法参见文献(Shu-Juan Piao，et al.,Hippolachnin A,a New Antifungal Polyketide from the South China Sea SpongeHippospongia lachne.Organic Letters，2013,15(14):3526–3529.)，按照上述方法制备化合物Hippolachnin A。
实施例1：本发明所涉及化合物Hippolachnin A片剂的制备：
取5克化合物Hippolachnin A,加入糊精195克，混匀，常规压片制成1000片。
实施例2：本发明所涉及化合物Hippolachnin A胶囊剂的制备：
取5克化合物Hippolachnin A，加入淀粉195克，混匀，装胶囊制成1000粒。
下面通过药效学实验来进一步说明其药物活性。
实验例1：Hippolachnin A对急性肾衰大鼠的治疗作用
(一)实验方法
采用肌肉注射甘油致急性肾功能衰竭大鼠动物模型。选用180～220g健康雄性SD大鼠60只，南京医科大学实验动物中心，随机分为5组：假手术组(肌肉注射生理盐水)；模型组(肌肉注射甘油)；Hippolachnin AⅠ组(0.3mg/Kg))；Hippolachnin AⅡ组(0.6mg/Kg))；Hippolachnin AⅢ组(1.2mg/Kg))，各组大鼠在甘油造模后立即尾静脉注射生理盐水或Hippolachnin A，12和24小时后再给药一次。
(二)观察指标
60只大鼠末次给予Hippolachnin A或生理盐水后放入代谢笼收集24小时尿，留尿后6小时用4％水合氯醛腹腔注射麻醉，采用激光多普勒血流仪测定造模后及治疗后双侧肾脏血流量，取平均值作为单只动物肾血流量；取血制备血清，测定血BUN和Cre；取肾脏，制备10％肾皮质匀浆，测定肾皮质匀浆MDA、GSH、NO(均按试剂盒说明书操作)。
(三)实验结果
1.Hippolachnin A可增加急性肾衰小鼠肾血流量
表1Hippolachnin A对急性肾衰小鼠肾血流量的影响
*P<0.05与急性肾衰模型组对比
2.Hippolachnin A对急性肾衰小鼠肾功能具有保护作用
模型组大鼠较假手术组大鼠24小时尿量显著减少，分别为4.57±0.74ml和11.82±2.36ml；中、高剂量Hippolachnin A组24小时尿量显著高于模型组(P<0.05)，三个药物治疗组的尿量具有剂量依赖性，分别为Ⅰ组5.48±0.87ml，Ⅱ组7.82±1.32ml，Ⅲ组9.68±1.50ml。说明Hippolachnin A能改善急性肾衰大鼠的少尿症状。
急性肾衰大鼠静脉注射生理盐水24小时后，血清BUN为25.53±1.62mmol/L，Cre为168.56±13.01umol/L，明显高于假手术组，说明模型组动物肾功能损害严重。中、高剂量Hippolachnin A能剂量依赖性地改善急性肾衰大鼠的肾功能(P<0.05)。见表2。
表2各试验组大鼠肾功能指标比较
*P<0.05与急性肾衰模型组对比
结论：Hippolachnin A能够改善急性肾衰时的无尿或少尿症状，保护肾脏的功能,可以用来制备抗急性肾衰药物。

Claims (1)

1.Hippolachnin A在制备治疗急性肾衰药物中的应用，所述化合物HippolachninA结构如式(Ⅰ)所示：
CN201310652101.2A 2013-12-05 2013-12-05 Hippolachnin A在治疗急性肾衰药物中的应用 Active CN103655538B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310652101.2A CN103655538B (zh) 2013-12-05 2013-12-05 Hippolachnin A在治疗急性肾衰药物中的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310652101.2A CN103655538B (zh) 2013-12-05 2013-12-05 Hippolachnin A在治疗急性肾衰药物中的应用

Publications (2)

Publication Number Publication Date
CN103655538A CN103655538A (zh) 2014-03-26
CN103655538B true CN103655538B (zh) 2015-09-23

Family

ID=50295101

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310652101.2A Active CN103655538B (zh) 2013-12-05 2013-12-05 Hippolachnin A在治疗急性肾衰药物中的应用

Country Status (1)

Country Link
CN (1) CN103655538B (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603689A (zh) * 2011-05-31 2012-07-25 上海长征医院 降二萜类化合物莱茄萜a及其制备方法和用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603689A (zh) * 2011-05-31 2012-07-25 上海长征医院 降二萜类化合物莱茄萜a及其制备方法和用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hippolachnin A, a new antifungal polyketide from the south china sea sponge hippospongia lachne;Shu-juan Piao等;《organic letters》;20130705;第15卷(第14期);3526-3529 *
急性肾衰发病机制及肾保护研究新进展;王爱忠 等;《国外医学》;20001231;第21卷(第2期);84-86 *
急性肾衰竭的治疗;张莉华;《中外健康文摘》;20130430;第10卷(第17期);6-8 *

Also Published As

Publication number Publication date
CN103655538A (zh) 2014-03-26

Similar Documents

Publication Publication Date Title
CN103599102B (zh) Nitrosporeusines A在治疗急性肾衰药物中的应用
CN103655538B (zh) Hippolachnin A在治疗急性肾衰药物中的应用
AU2017206332B2 (en) Use of Cistanche tubulosa extract and isoacteoside in protection of muscles
CN103599105B (zh) Caesanines D在制备治疗急性肾衰药物中的应用
CN102872115B (zh) Houttuynoid A在制备治疗急性肾衰药物中的应用
CN103520172B (zh) Kadcoccitones A在制备治疗急性肾衰药物中的应用
CN103356646B (zh) Chukrasone A在制备治疗急性肾衰药物中的应用
CN103356605B (zh) Chukrasone B在制备治疗急性肾衰药物中的应用
CN103446119B (zh) Fluevirosines A在制备治疗急性肾衰药物中的应用
CN103251637A (zh) Polyflavanostilbene A在制备治疗急性肾衰药物中的应用
CN102861095B (zh) Houttuynoid E在制备治疗急性肾衰药物中的应用
CN105287529A (zh) Lycojaponicumins A在制备治疗急性肾衰药物中的应用
CN105456238A (zh) Norsampsone A在制备治疗急性肾衰药物中的应用
CN105287481A (zh) Concrescenin A在制备治疗急性肾衰药物中的应用
CN105078954A (zh) 一种治疗急性肾衰药物及其应用
CN102872140B (zh) Houttuynoid C在制备治疗急性肾衰药物中的应用
CN106389420A (zh) Ternatusine A在制备治疗急性肾衰药物中的应用
CN105497040A (zh) Astataricusol A在制备治疗急性肾衰药物中的应用
CN102872094A (zh) Houttuynoid B在治疗急性肾衰药物中的应用
CN102861008A (zh) Aphanamixoid A在治疗急性肾衰药物中的应用
CN103462996A (zh) Neonectrolide A在制备治疗急性肾衰药物中的应用
CN103463009A (zh) Racemosins A在制备治疗急性肾衰药物中的应用
CN103127151A (zh) Gypensapogenin A在治疗急性肾衰药物中的应用
CN103340877A (zh) Aspeverin在制备治疗急性肾衰药物中的应用
CN105919996A (zh) 一种治疗急性肾衰药物组合物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NANJING ZHENGLIANG PHARMACEUTICAL TECHNOLOGY CO.,

Free format text: FORMER OWNER: CHANGZHOU COLLECTION MEDICAL INSTRUMENT CO., LTD.

Effective date: 20150420

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 213000 CHANGZHOU, JIANGSU PROVINCE TO: 211200 NANJING, JIANGSU PROVINCE

TA01 Transfer of patent application right

Effective date of registration: 20150420

Address after: Qingfeng Village Yong Yang town of Lishui County of Nanjing City, Jiangsu province 211200 Green Village building 301 room 22

Applicant after: Nanjing Zhengliang Medical Technology Co.,Ltd.

Address before: 213000 West -256-1, building 4, West Taihu international wisdom garden, Wujin Economic Development Zone, Jiangsu, Changzhou

Applicant before: CHANGZHOU KELIXIN MEDICAL DEVICES CO., LTD.

ASS Succession or assignment of patent right

Owner name: LIU YANJIAO

Free format text: FORMER OWNER: NANJING ZHENGLIANG PHARMACEUTICAL TECHNOLOGY CO., LTD.

Effective date: 20150827

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent for invention or patent application
CB03 Change of inventor or designer information

Inventor after: Sun Dehong

Inventor after: Huang Shusheng

Inventor before: Chen Jun

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: CHEN JUN TO: SUN DEHONG HUANG SHUSHENG

TA01 Transfer of patent application right

Effective date of registration: 20150827

Address after: 235000 Anhui Province, Huaibei City Xiangshan District Anhui Hengyuan coal Limited by Share Ltd dormitory

Applicant after: Liu Yanjiao

Address before: Qingfeng Village Yong Yang town of Lishui County of Nanjing City, Jiangsu province 211200 Green Village building 301 room 22

Applicant before: Nanjing Zhengliang Medical Technology Co.,Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: 225324 Jiangsu province Taizhou Gaogang Xu Zhuang Street Minghe Village No. 53

Patentee after: Liu Yanjiao

Address before: 235000 Anhui Province, Huaibei City Xiangshan District Anhui Hengyuan coal Limited by Share Ltd dormitory

Patentee before: Liu Yanjiao

C41 Transfer of patent application or patent right or utility model
CB03 Change of inventor or designer information

Inventor after: Shi Xinlong

Inventor after: Ma Zhe

Inventor after: Wei Min

Inventor after: Zhang Yao

Inventor after: Sun Chuanchang

Inventor before: Sun Dehong

Inventor before: Huang Shusheng

COR Change of bibliographic data
TR01 Transfer of patent right

Effective date of registration: 20160202

Address after: 101500 Beijing Miyun City Economic Development Zone No. 1 strong cloud

Patentee after: Beijing Sino pharmaceutical factory

Address before: 225324 Jiangsu province Taizhou Gaogang Xu Zhuang Street Minghe Village No. 53

Patentee before: Liu Yanjiao

CP01 Change in the name or title of a patent holder

Address after: 101500 Beijing Miyun City Economic Development Zone No. 1 strong cloud

Patentee after: Beijing Sino pharmaceutical Limited by Share Ltd

Address before: 101500 Beijing Miyun City Economic Development Zone No. 1 strong cloud

Patentee before: Beijing Sino pharmaceutical factory

CP01 Change in the name or title of a patent holder
CP02 Change in the address of a patent holder

Address after: 101500 No. 1, Qiang Yun Road, Miyun District Economic Development Zone, Beijing

Patentee after: Beijing Sino pharmaceutical Limited by Share Ltd

Address before: 101500 Beijing Miyun City Economic Development Zone No. 1 strong cloud

Patentee before: Beijing Sino pharmaceutical Limited by Share Ltd

CP02 Change in the address of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 101500 No. 1 Qiangyun Road, Miyun Economic Development Zone, Beijing

Patentee after: Beijing Haiwang Zhongxin Pharmaceutical Co.,Ltd.

Address before: 101500 No. 1 Qiangyun Road, Miyun Economic Development Zone, Beijing

Patentee before: Beijing Sino pharmaceutical Limited by Share Ltd.

CP01 Change in the name or title of a patent holder